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Abstract
Purpose Lateral internal sphincterotomy has been the gold
standard treatment for chronic anal fissure, but it still carries
the risk of permanent damage of the anal sphincter, which
has led to the implementation of alternative treatment like
botulinum toxin injection. The aim of this randomized pro-
spective controlled trial was to compare the efficacy and
morbidity of botulinum toxin injection and lateral internal
sphincterotomy in the treatment of chronic anal fissure.
Methods Fifty consecutive adults with chronic anal fissure
were randomly treated with either lateral internal sphincter-
otomy or botulinum toxin (BT) injection with 50 U BT into
the internal sphincter. The complications, healing and recur-
rence rate, and incontinence score were assessed 2, 3, 6, 12
months after the procedure.
Results Inspection at the 2-month visit revealed complete
healing of the fissure in 11 (44 %) of the patients in the BT
group and 22 (88 %) of the patients in the lateral internal
sphincterotomy (LIS) group (p00.001). At the 3-month
visit, there was no significant difference between the two
groups in healing. The overall recurrence rate after 6 months
in the BT group was higher than in the LIS group (p<0.05).
In the 3-month follow-up, the LIS group had a higher rate of
anal incontinence compared to the BT group (p<0.05). The
final percentage of incontinence was 4 % in the LIS group
(p>0.05).
Conclusions The treatment of chronic anal fissure must be
individualized depending on the different clinical profiles of
patients. Botulinum toxin injection has a higher recurrence
rate than LIS, and LIS provides rapid and permanent recov-
ery. However, LIS carries a higher risk of anal incontinence
in patients.
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Introduction
Anal fissure remains one of the most common proctologic
problems which cause severe sharp pain on defecation,
occasionally accompanied by bleeding [1–3]. The pain as-
sociated with chronic anal fissure (CAF) leads to propor-
tionate worsening of quality of life and tends not to heal
without intervention [4, 5]. Breaking the vicious cycle of
spasm, ischemia, and pain in CAF is accomplished with
surgical or medical procedures. Today, lateral internal
sphincterotomy (LIS) remains the gold standard for treatment
of chronic anal fissure. This operation has been successful in
more than 90 % of cases and has rates of recurrence smaller
than 10 % [6–8]. However, it carries the risk of permanent
complications [1] like fecal incontinence in up to 30 % of
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patients [9]. This has led to the studies and implementation of
other alternative medical treatments, mainly botulinum toxin
injection [10–14] and organic nitrate preparations [15–17]. Of
these, botulinum toxin injection seems to be an optimal non-
operative therapy with similar healing rates [18] but lowest
rate of recurrence [12] and fewest side effects [19], and studies
have shown no permanent damage to the continence mecha-
nism that was detected in patients treated with botulinum toxin
[20–22].
The aim of this randomized prospective controlled study
was to compare the efficacy and morbidity of botulinum
toxin injection and lateral internal sphincterotomy in the
treatment of chronic anal fissure.
Materials and method
Patients
Between January 2007 and January 2009, 50 consecutive
adults with chronic anal fissure were included in our study.
All the patients diagnosed bymedical history (bleeding and/or
pain during or after defecation for at least 3 months) and
physical examination including digital anal examination and
anuscopy. Conservative treatment (high-residue diet, warm
sitz baths, and analgesics) had failed in these patients. The
diagnosis of the chronic anal fissure was based on the follow-
ing criteria: evidence of posterior or anterior circumscribed
ulcer with a sentinel tag of skin, indurations at the edges, and
exposed internal sphincter fibers. The exclusion criteria were
complicated fissure (fistula, stenosis, abscess, and symptom-
atic hemorrhoids), large sentinel pile, associated disease (in-
flammatory bowel disease, tuberculosis, malignancy, prior
pelvic radiotherapy, and any immunosuppressive condition),
allergy to local anesthetics, and patients who had undergone
previous surgical procedure in the anal canal.
This study was done in Ayatollah Taleghani Hospital,
Shahid Beheshti University of Medical Science and was
approved by the ethics committee of Ayatollah Taleghani
Hospital. An informed consent was signed by each patient
before participating in the study.
Study design
The patients were categorized into two groups by the com-
puter randomization program: group 1 underwent surgical
sphincterotomy (n025) and group 2 underwent chemical
sphincterotomy with botulinum toxin (n025).
Lateral internal sphincterotomy
All the procedures were performed by the same surgeon
using a similar method in the lithotomy position. Lateral
internal sphincterotomy was done under spinal anesthesia.
The lateral anal region was exposed with an anal retractor
through a 1.5 to 2-cm circumferential incision placed out-
side the anal verge. Internal and external sphincters were
separated using the intersphincteric plane, and the internal
sphincter was assessed under direct vision and about 50 %
of the sphincter was incised. The skin incision was either
closed with interrupted sutures or was left open, and skin
tags were removed as a routine.
Botulinum toxin injection
Botulinum toxin injection was performed under local anes-
thesia (xylocaine gel 5 %). A 100-U vial of type A lyoph-
ilized botulinum (BOTOX, Allergan, CA) stored at −20 °C,
diluted with salin to 50 U/ml on the day of injection. With a
so-called insulin syringe (26-G needle), 25 U was injected
into each side of the sphincter. In patients with posterior
fissure, BTwas injected on each side of the anterior midline,
and in patients with anterior fissure, BT was injected on
each side of the posterior midline.
Postoperative follow-up
In both groups, conservative treatments including high-
residue diet and warm sitz baths were recommended to control
constipation and decrease pain and bleeding. At the time of
admission, documents regarding age, gender, symptoms
(pain, bleeding, and constipation), duration of symptoms,
and physical examination findings (skin tag, site of fissure)
were collected. Early complications were collected at 1 week
visit. Postoperative follow-ups regarding degree of fissure
healing, different types of incontinence, and relapse of the
fissure were collected at 2 weeks and 2, 3, 6, 12 months
follow-up visits. All the patients were examined by the same
surgeon at the outpatient department of Ayatollah Taleghani
Hospital. Complete healing was considered as complete re-
epithelialization of fissure and absence of symptoms. Partial
healing was defined as initiation of epithelialization and re-
duction of symptoms. Persistence of fissure whether associat-
ed with symptoms or not were considered as recurrent fissure.
The validated Cleveland Clinic scoring system was used for
assessment of continence severity. The system gives points for
each degree of incontinence, whether gas (1–3), liquid stool
(4–6), solid stool (7–9), or the requirement of wearing a pad
(1–3) according frequency (occasionally, >1/week or daily),
respectively. The Cleveland score is the sum of those points:
00perfect continence, 1–70good continence, 8–140moder-
ate continence, 15–200severe incontinence, and 210com-
pletely incontinent [23, 24]. The treatment was considered
successful if the CAF was healed completely within 2 months
after treatment. Unhealed fissures were considered as failure
of treatment. According to Table 1, the two groups were
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almost similar in characteristics and symptoms, and there was
no significant difference between them in anal exploration
before treatment.
Statistical analysis
The data are analyzed with the aid of the SPSS 11.5 com-
puter program, and continuous variables are expressed as
means ± SD. Statistical significance of CAF healing and
incontinency, etc. in the two groups is analyzed with the chi-
square test and 95 % confidence interval. Probability values
of less than 0.05 were considered significant. Considering
the power of our study as 0.7 and effect size as 0.5, the
sample size was calculated as 25 patients in each group.
Results
Early complications occurring after procedures were hema-
toma in 1 (4 %) patient and also self-limited hemorrhage in
2 (8 %) patients in the surgical sphincterotomy group. There
were no anal abscesses, perianal fistulae, urinary retention,
and hemorrhoid thrombosis in our patients.
There was complete healing of fissure in seven patients
(28 %) in the BT group and ten patients (40 %) in the LIS
group at the 2-week visit, and partial healing was found in
five patients (20 %) of each group. Inspection at the 2-
month visit revealed a statistically significant higher rate
of complete healing in the LIS group than in the BT group
(p00.001). According to the healing classification in our
study, nine and one patient in the BT and LIS group had a
partial healing, respectively. Considering partial healing as a
start of the healing process, there was no significant differ-
ence in the rate of healing between the two groups, and the
data analysis at the 3-month visit showed no significant
difference between the two groups (p>0.05) (Table 2).
In patients in whom the symptoms duration had been pres-
ent for longer than 12 months in both groups, fissures were
significantly less likely to heal (p00.028 in BT group, p0
0.014 in LIS group). There was no relationship found between
the other preoperative clinical variables analyzed and healing.
Evaluation of the persistence or recurrence of the fissures
after 6 months revealed a significantly higher rate of recur-
rence in the BT group than in the LIS group (p00.005).
Significant differences in overall healing were found after
12 months follow-up; 12 patients (48 %) in the BT group
and 23 patients (92 %) in the LIS group (p00.001). Fissures
were less likely to relapse in patients with symptom duration
less than 12 months in the LIS and the BT group (p00.003
in the BT group, p00.014 in the LIS group). There was no
relationship found between the other preoperative clinical
variables and recurrence.
Inspection of patients in the BT group at 2 weeks after
treatment revealed a complete healing in seven patients
Table 1 Characteristics and
symptoms of patients and anal
examination results before
treatment
Group 1 (n025) lateral
internal sphincterotomy
Group 2 (n025) toxin
botulinum
Mean age (year) 36.4±8.5 34.8±8.1
Gender (men/women) 8 (32 %)/17 (68 %) 11 (44 %)/14 (56 %)
Symptoms duration (months) 9.07±4.8 11.4±4.8
Site of fissure
Posterior midline 20 (80 %) 19 (76 %)
Anterior midline 5 (20 %) 6 (24 %)
Skin tag 18 (72 %) 17 (65.4 %)
Pain 23 (92 %) 22 (88 %)
Bleeding 21 (84 %) 19 (76 %)
Constipation 14 (56 %) 16 (64 %)
Pruritus 11 (44 %) 8 (32 %)
Table 2 Healing rate and in-
continence in the two groups Healed fissures p Incontinence p
Follow-up visits BT group LIS Group BT group LIS group
2 months 11 (44 %) 22 (88 %) 0.001 3 (12 %) 12 (48 %) 0.005
3 months 20 (80 %) 23 (92 %) >0.05 0 5 (20 %) <0.05
6 months 13 (52 %) 22 (88 %) 0.005 0 4 (16 %) <0.05
12 months 12 (48 %) 23 (92 %) 0.001 0 1 (4 %) >0.05
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(28 %), partial healing in five patients (20 %), and no
healing in 13 patients (52 %). Of the patients in whom no
healing was found in the 2-week visit, ten patients had a
recurrent or persistent fissure at the end of the study (76 %).
There was a significant higher rate of recurrence in patients
with unhealed fissures at 2-week visit than patients with
partial or complete healing (p00.023).
In the 3-month follow-up, moderate incontinence (Cleve-
land Clinic scoring system (8–14)) was present in five
patients (20 %) in the LIS group and none of the patients
in the BT group suffered anal incontinence (p00.018). Six
months after LIS, anal incontinence has resolved in one
patient, spontaneously. At the end of the study, after 12
months, only one patient from the LIS group (4 %) reported
occasional incontinence to gas or liquid stool (Cleveland
Score, <7) (Table 2). Occurrence of anal incontinence after
LIS was significantly higher in age >40 years (p00.022)
(Table 3).
Discussion
Since botulinum toxin injection was introduced as a poten-
tial treatment for anal fissures in 1993 [25], various studies
compared the efficacy of this treatment to surgical methods
in the treatment of fissures [26–29]. Because of different
results and unclear conclusions, there is still controversy on
whether BT injection is a suitable substitute for LIS in
treatment of CAF.
Some studies suggest chemical sphincterotomy methods
like BT injection as a first choice in treatment of CAF
because they are relatively less expensive and less invasive
than surgery [30, 31], and there were studies with results
suggesting that BT injection has an equal healing rate com-
pare with LIS [32]. The best healing results in the short-term
follow-up have been (>80 %) in the studies about the use of
BT in the treatment of anal fissures [13, 33]. However,
longer follow-up in some other studies shows a progressive
recurrence over time with lower rate of healing than initial
reports and relapse of anal fissure in 55 % of patients at 3
years [27] and 41.5 % at 42 months [34]. This could be
related to the fact that relaxation of smooth internal anal
sphincter produced by the botulinum toxin is not permanent,
and the clinical efficacy lasts only for 2–3 months after
injection [35]. In our study, there was also a progressive
rate of recurrence of fissure in the BT group which starts at
19.2 % in 3 months and reaches 50 % in 12 months. The end
point of our study was 12 months because according to
Arroyo et al. [27], recurrence occurs mainly between 6 and
12 months so later relapses is not expected. The recurrence
rate of surgical sphincterotomy was 8 % and not progressive.
Studies suggested that some clinical factors like posterior
localized fissure and short duration of symptoms (<12
months) are predictive factors for a favorable outcome in BT
toxin treatment in CAF [34, 36]. In our study, we found
duration of symptoms as a clinical parameter related to a
higher rate of recurrence. In the BT group, the mean duration
of symptoms was 11 months and in the LIS group it was 9
months. This difference could be responsible for the higher
rate of recurrence for patients treated with BT. Therefore, we
believe that LIS seems to be a better option for these patients
as a first therapeutic option considering higher probability of
recurrence with BT treatment in the long term follow-up.
Different studies have used varying dosage regimens of
botulinum toxin but in most of them a single injection of
20–30 U was employed [18, 28, 29]; however, there was
studies that have suggested higher doses (up to 50 U)
provide a higher success rate (up to 96 %) without a signif-
icant rising in complications or side effects [37]. In this
study, we used 50 U and it did not cause any rise in
complication rate. In addition, the site of injection of BT
toxin is an important parameter in success rate of BT
Table 3 Correlation between the healing of fissure, incontinence, and fissure recurrence and preoperative variables following botulinum toxin
injection and surgical sphincterotomy














<40 18 8 0 9 16 15 1 2
>40 7 3 0 3 9 7 4 1
Male/female 11/14 3/8 0 6/6 8/17 7/15 2/3 1/2
Duration, months
<12 12 8 0 2 16 16 2 0
≥12 13 3 0 10 9 6 3 3
Anterior/posterior fissure 6/19 1/10 0 3/9 5/20 4/18 0/5 1/2
Skin tag 17 6 0 9 18 17 5 2
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treatment. According to the study of Maria et al. [13], to
reduce the resting pressure of anal sphincter efficiently, we
injected BT into the internal anal sphincter on each side of
fissure.
By analyzing the immediate complication rate (hemor-
rhage, hematoma, anal abscess, fistula, urinary retention,
and hemorrhoid thrombosis), there was no significant dif-
ference between two groups. In our study, the rate of incon-
tinence after 12 months was 4 % in the LIS group while
there was no incontinence in the BT group. Although the
difference was not statistically significant, considering the
specific impacts of incontinence on quality of life [38], the
LIS advantages in treatment of the CAF will be nullified. An
age of >40 was the only pretreatment factor associated with
an increase in incontinence. Based on these findings, Botox
therapy might be considered as the first therapeutic ap-
proach in patients with high surgical risks or those who
avoid surgery or in cases with high risk of future inconti-
nence (age greater than 40, women with multiple vaginal
deliveries, inflammatory bowel diseases, prior anal surgery,
prior incontinence, etc.) despite the higher rate of recurrence
and reoperation, cause BT injection is relatively safe and
leads to no detriment to continence. In addition, BT
treatment represents a simple outpatient procedure without
anesthesia or incision which makes it a relatively less
expensive and less invasive procedure than LIS. These
advantages make BT injection an effective alternative for
treatment of chronic anal fissure. On the other hand, BT
injection was performed in a blind manner and dislocation
of this injection is inevitable while LIS is performed under
direct vision so it is a more reproducible procedure.
In our study, we found that in the BT group, patients with
no healing at 2-week visit tend to relapse or not heal during
follow-up, and the recurrence rate is relatively lower in
patients who have been healed at 2-week visit. Based on
these results, we suggest that patients who remained un-
healed 2 weeks after the BT injection seems to need other
procedures like LIS to achieve better results.
Although all the patients underwent conservative man-
agement before recruitment to this study, there is always a
possibility that fissures can be healed without any interven-
tion. Using a control group could eliminate this problem,
and this can be a limitation of current study and should be
focused in the future studies.
Conclusion
The treatment of chronic anal fissure must be individualized
depending on the different clinical profiles of the patients.
Botulinum toxin injection has a higher recurrence rate than
LIS, and LIS provides rapid and permanent recovery. How-
ever, LIS carries a higher risk of anal incontinence in patients.
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